Interview with Darren Ji, CEO, PharmaLegacy
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
Address: Building 7, 388 Jialilue Rd.,Zhangjiang High-Tech Park, Shanghai,China
Tel: (86) 21-6100 2280
Web: http://www.pharmalegacy.com/Home.aspx?lang=en
PharmaLegacy Laboratories is a leading preclinical Contract Research Organization (CRO) providing specialty pharmacology services in Bone Metabolism, Immune Diseases, Inflammation, Oncology, and Orthopaedics and Tissue Engineering. The core competency of PharmaLegacy stems from our pioneering work and expertise in developing and running specialized animal models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. We also conduct adjacency studies in PK/PD, molecular pharmacology and preliminary toxicology. Overall we provide one-stop shopping of preclinical pharmacology services for early proof of concept of therapeutics and fulfillment of regulatory requirement.
Aspiring to collaborate with our global clients to accelerate their missions to develop new therapies, PharmaLegacy provides quality services with faster turnaround and higher productivity of R&D to IND/IDE endeavors for pharmaceutical, biotech, and orthopaedic device companies around the world.
The PharmaLegacy management team consists of world-renowned scholars, top service scientists and seasoned business leaders from the US and Shanghai. We have fully established animal pharmacology models of rodents, rabbits, dogs, sheep, goats and non-human primates which are used to serve our current clients of large multinational pharmaceutical and medical device companies, as well as small- to-medium-sized biotech companies.
Research
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
Writing in the April edition of DIA’s Global Forum magazine, the DIA China Leadership and Career Community look at the Chinese pharmaceutical innovation ecosystem’s R&D talent gap and the China Pharmaceutical R&D…
As China struggles to maintain its ‘dynamic zero-COVID’ policy in the face of Omicron variant outbreaks, other key talking points emerging from the world’s second-largest healthcare and life sciences market…
Bridge Consulting’s Zoe Leung examines the journeys of Chinese-developed COVID-19 vaccines outside of China’s borders, drawing on a number of examples, from Sinopharm’s work on boosting vaccine supply in the…
Despite rapidly developing and rolling out two vaccines against COVID-19 – from domestic firms Sinopharm and Sinovac – China is yet to approve a vaccine that uses mRNA technology, either…
The latest news from Chinese healthcare and pharma including Western pharmacos’ moves to license therapies from Chinese partners to sell globally, the seismic impact of new COVID lockdown restrictions in…
Writing in the March 2022 edition of DIA’s Global Forum magazine, Jessie Zhu of Deltamed Co. Ltd./Pharmaron Clinical and Monica Juping Xu of Taimei Medical Technology outline the progress of…
Having consolidated its position as Asia’s largest biotech fundraising hub – and the world’s second largest – the Hong Kong Stock Exchange (HKEX) listed a total of 34 biotech and…
A selection of recent top stories from the Chinese pharma industry, including China’s conditional approval of Pfizer’s COVID treatment pill Paxlovid; a new push to combat monopoly practices and unfair…
PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective pharmacovigilance ecosystem is helping to safeguard the rollout of…
Some of the biggest stories across China’s healthcare and life science industry today, including the 61.7 percent average price reduction Big Pharma took to get their drugs listed on China’s…
The latest news from Chinese pharma, including an examination of the new national reimbursement drug list (NRDL), the therapies that have and have not made it onto the list, and…
The phenomenal success of the Pfizer/BioNTech and Moderna COVID-19 vaccines has catapulted messenger RNA (mRNA) vaccines into public consciousness, and mRNA technology is today receiving more scientific and financial attention…
See our Cookie Privacy Policy Here
